Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer

被引:1
|
作者
Kadkhodayan, Sima [1 ]
Shandiz, Fatemeh Homaei [2 ]
Toussi, Mehdi Seilanian [2 ]
Aghaee, Monavar Afzal [3 ]
Farshidi, Farnoosh [4 ]
Dehghan, Parvane [5 ]
机构
[1] Mashhad Univ Med Sci, Ghaem Hosp, Womens Hlth Res Ctr, Mashhad, Iran
[2] Mashhad Univ Med Sci, Ghaem Hosp, Solid Tumor Treatment Res Ctr, Mashhad, Iran
[3] Mashhad Univ Med Sci, Dept Epidemiol, Mashhad, Iran
[4] Mashhad Univ Med Sci, Ghaem Hosp, Mashhad, Iran
[5] Mashhad Univ Med Sci, Dept Radiat Oncol, Mashhad, Iran
关键词
Cervical cancer; Radiotherapy; Concurrent chemoradiotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy. Methods: In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated. Results: 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2year overall survival rate of 58.7% +/- 9% and 2-year disease free survival of 37.7% +/- 9%. Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded. Conclusion: Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 50 条
  • [1] CONCURRENT CHEMORADIOTHERAPY WITH HIGH-DOSE-RATE BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER
    Kim, Y. S.
    Kim, J. H.
    Lee, S. W.
    Yoon, S. M.
    Ahn, S. D.
    Choi, E. K.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S310 - S310
  • [2] SURGERY AFTER CONCURRENT CHEMORADIOTHERAPY AND BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER: MORBIDITY AND OUTCOME
    Aloui, Marwa
    Zemni, Ines
    Sakhri, Saida
    Jaouadi, Souha
    Chargui, Riadh
    Ben Dhied, Tarek
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A100 - A100
  • [3] Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer
    Jakubowicz, J.
    Blecharz, P.
    Skotnicki, P.
    Reinfuss, M.
    Walasek, T.
    Luczynska, E.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (04) : 393 - 399
  • [4] GLAC: combined chemoradiotherapy and brachytherapy in locally advanced cervical cancer
    de la Torre, M
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S3 - S3
  • [5] Operation for locally advanced cervical cancer after concurrent chemoradiotherapy
    Junli Ge
    Jidong Sun
    Jia Li
    Qianfeng Zhang
    Xiaohui Lv
    Biliang Chen
    [J]. International Journal of Clinical Oncology, 2020, 25 : 948 - 954
  • [6] Operation for locally advanced cervical cancer after concurrent chemoradiotherapy
    Ge, Junli
    Sun, Jidong
    Li, Jia
    Zhang, Qianfeng
    Lv, Xiaohui
    Chen, Biliang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 948 - 954
  • [7] Adjuvant Chemotherapy after Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
    Kou, L.
    Zhang, T.
    Peng, S.
    Wang, Y.
    Yuan, M.
    Li, M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S51 - S52
  • [8] Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?
    Leguevaque, Pierre
    Motton, Stephanie
    Delannes, Martine
    Querleu, Denis
    Soule-Tholy, Marc
    Tap, Gerard
    Houvenaeghel, Gilles
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 155 (02) : 188 - 192
  • [9] Late recurrence of locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Janmunee, Narumon
    Tangkananan, Aimwarin
    Thongkhao, Pitchaya
    Hanprasertpong, Jitti
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (06): : 393 - 401
  • [10] Outcomes of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer
    Liu, Yan-Mei
    Liu, Hui
    Sun, Hua-Li
    Xu, Yuan-Yuan
    Ding, Yan
    Chen, Wei-Jun
    Ying, Shen-Peng
    [J]. NEOPLASMA, 2021, 68 (03) : 645 - 651